Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients

September 9, 2014 A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings are being presented by The University of Texas MD Anderson Cancer Center at the 2014 American Society of Clinical Oncology’s Breast Cancer …

OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial

Funding to support expanded clinical development of PVX-410 in combination with lenalidomide in patients with smoldering multiple myeloma Financing includes equity investment from The Leukemia & Lymphoma Society August 28, 2014 OncoPep, Inc., today announced the closing of $6.9 million in Series B financing from new and existing investors. The financing included participation from angel groups, family foundations and individuals, …

USU-HJF Effort to License Promising Breast Cancer Vaccine Wins Award

April 23, 2014 A joint effort by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and the Uniformed Services University of the Health Sciences (USU) to license a promising breast cancer vaccine to reduce breast cancer recurrence rates has received the 2014 Award for Excellence in Technology Transfer. This marks the second consecutive award for …

MD Anderson, MedImmune Join Forces to Advance Cancer Immunotherapy

March 13, 2014 The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson’s Moon Shots Program to develop therapies that unleash patients’ immune systems to attack their cancers. “Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to …

Engineering flaw may render cancer vaccines ineffective

Some cancer vaccines may be ineffective because of an engineering flaw in the vaccine's design, a study has found. Research performed at Texas MD Anderson Cancer Center and published in Nature Medicine examined the T cell responses elicited in mice after vaccination with the cancer vaccine gp100 melanoma peptide. The aim of the cancer immunotherapy is to increase the levels …

The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Northwest Biotherapeutics, Inc.

June 25, 2014 Levi & Korsinsky, LLP is investigating Northwest Biotherapeutics, Inc. (“Northwest Bio” or the “Company”) in connection with possible breaches of federal securities laws. The investigation regards concerns that the Company made misleading statements regarding its clinical trial for DC-Vax Direct, its experimental cancer vaccine. To get more information, click here: http://zlk.9nl.com/northwest-biotherapeutics-nwbo. There is no cost or obligation to …